



**Time-course MALDI-TOF-MS serum peptide
profiling of non-small cell lung cancer patients
treated with bortezomib, cisplatin and
gemcitabine**

Jens Voortman^{*}, Thang V Pham^{*}, Jaco C Knol, Giuseppe Giaccone
and Connie R Jimenez

In preparation

^{*} Equally contributed